Previous 10 | Next 10 |
2024-02-02 17:15:25 ET More on Moleculin Biotech Moleculin Biotech, Inc. (MBRX) Q3 2023 Earnings Call Transcript Moleculin Biotech stock slides on pricing $4.5 million securities offering Moleculin Biotech gains after early data for lead cancer therapy Seekin...
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3 PR Newswire – MB-106 AML Phase 1B /2 trial (MB-106) preliminary data readout: Reached 67% recruitment ...
2023-12-21 01:31:33 ET More on Moleculin Biotech Moleculin Biotech gains after early data for lead cancer therapy Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biote...
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market PR Newswire HOUSTON , Dec. 20, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage ph...
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting PR Newswire - CR rate of 36% in Intent to Treat or ITT (n=11) subjects with durability - CR rate of 44% in subjects treated with ...
2023-11-13 15:28:21 ET More on Moleculin Biotech Moleculin Biotech, Inc. (MBRX) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotec...
2023-11-13 12:59:02 ET Moleculin Biotech, Inc. (MBRX) Q3 2023 Earnings Conference Call November 13, 2023, 08:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman & CEO Paul Waymack - Senior CMO Jonathan Foster - EVP & CFO Con...
2023-11-13 10:59:58 ET More on Moleculin Biotech Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotech For further details see: Moleculin Biotech Q3 GAAP EPS of ...
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months PR Newswire – MB-106: CR rate of 38% (N=8) with durability u...
Moleculin Reports Third Quarter 2023 Financial Results PR Newswire – Ends Quarter with $24.6 million in Cash with Runway Estimated into Third Quarter of 2024 – Third quarter marked by additional positive clinical data from Annamycin lead development p...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress PR Newswire HOUSTON , May 16, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage ...
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) PR Newswire – Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin ...
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire – Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1 st an...